NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).

被引：0

作者：

Koontz, Bridget F.

Karrison, Theodore

Pisansky, Thomas Michael

Posadas, Edwin Melencio

Ballas, Leslie K.

Berlin, Alejandro

Hall, William A.

Tran, Phuoc T.

O'Daniel, Jennifer C.

Hope, Thomas A.

Rodgers, Joseph P.

Feng, Felix Y.

机构：

[1] GenesisCare USA, Ft Myers, FL USA

[2] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA

[3] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN USA

[4] Cedars Sinai Med Ctr, Cedars Sinai Canc, Los Angeles, CA USA

[5] Cedars Sinai Med Ctr, Los Angeles, CA USA

[6] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] Med Coll Wisconsin, Milwaukee, WI USA

[8] Univ Maryland, Baltimore, MD USA

[9] Duke Canc Inst, Durham, NC USA

[10] Univ Calif San Francisco, San Francisco, CA USA

[11] Amer Coll Radiol, NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS283

引用

页数：1